AllianceBernstein’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.76B Sell
4,427,764
-193,341
-4% -$196M 1.54% 9
2025
Q4
$4.97B Sell
4,621,105
-188,878
-4% -$181M 1.57% 9
2025
Q3
$3.67B Sell
4,809,983
-403,871
-8% -$301M 1.16% 10
2025
Q2
$4.06B Sell
5,213,854
-230,065
-4% -$179M 1.33% 10
2025
Q1
$4.5B Buy
5,443,919
+397,696
+8% +$331M 1.63% 10
2024
Q4
$3.9B Sell
5,046,223
-11,513
-0.2% -$9.53M 1.32% 11
2024
Q3
$4.48B Buy
5,057,736
+187,059
+4% +$168M 1.51% 9
2024
Q2
$4.41B Buy
4,870,677
+83,103
+2% +$66.5M 1.54% 8
2024
Q1
$3.72B Sell
4,787,574
-274,727
-5% -$196M 1.32% 9
2023
Q4
$2.95B Buy
5,062,301
+146,722
+3% +$85.6M 1.14% 9
2023
Q3
$2.64B Buy
4,915,579
+181,351
+4% +$93.4M 1.12% 8
2023
Q2
$2.22B Buy
4,734,228
+180,714
+4% +$75.8M 0.91% 14
2023
Q1
$1.56B Buy
4,553,514
+2,568,469
+129% +$866M 0.67% 24
2022
Q4
$726M Sell
1,985,045
-139,254
-7% -$49.4M 0.33% 70
2022
Q3
$687M Buy
2,124,299
+57,286
+3% +$18.2M 0.33% 61
2022
Q2
$670M Buy
2,067,013
+95,909
+5% +$28.8M 0.31% 68
2022
Q1
$564M Sell
1,971,104
-63,813
-3% -$16.4M 0.22% 89
2021
Q4
$562M Sell
2,034,917
-124,357
-6% -$31.5M 0.2% 95
2021
Q3
$499M Buy
2,159,274
+122,425
+6% +$30.2M 0.2% 96
2021
Q2
$467M Buy
2,036,849
+120,812
+6% +$24.3M 0.19% 104
2021
Q1
$358M Sell
1,916,037
-431,859
-18% -$84.5M 0.16% 129
2020
Q4
$396M Sell
2,347,896
-160,623
-6% -$24M 0.19% 102
2020
Q3
$371M Sell
2,508,519
-89,206
-3% -$13.8M 0.2% 93
2020
Q2
$426M Sell
2,597,725
-84,883
-3% -$13M 0.25% 77
2020
Q1
$372M Sell
2,682,608
-1,078,646
-29% -$148M 0.27% 75
2019
Q4
$494M Sell
3,761,254
-1,155,529
-24% -$134M 0.28% 80
2019
Q3
$550M Buy
4,916,783
+468,455
+11% +$52.2M 0.34% 62
2019
Q2
$493M Buy
4,448,328
+1,205,957
+37% +$142M 0.31% 68
2019
Q1
$421M Buy
3,242,371
+729,098
+29% +$88.7M 0.27% 76
2018
Q4
$291M Sell
2,513,273
-178,395
-7% -$19.9M 0.22% 101
2018
Q3
$289M Sell
2,691,668
-406,909
-13% -$40.7M 0.19% 110
2018
Q2
$264M Buy
3,098,577
+57,850
+2% +$4.75M 0.18% 114
2018
Q1
$235M Sell
3,040,727
-1,310,932
-30% -$106M 0.17% 126
2017
Q4
$368M Buy
4,351,659
+365,011
+9% +$31.1M 0.26% 90
2017
Q3
$341M Buy
3,986,648
+429,728
+12% +$35.2M 0.26% 98
2017
Q2
$293M Buy
3,556,920
+79,549
+2% +$6.49M 0.23% 104
2017
Q1
$292M Buy
3,477,371
+808,186
+30% +$64.7M 0.23% 97
2016
Q4
$196M Buy
2,669,185
+949,109
+55% +$70.7M 0.16% 129
2016
Q3
$138M Sell
1,720,076
-34,107
-2% -$2.73M 0.12% 173
2016
Q2
$138M Buy
1,754,183
+9,487
+0.5% +$714K 0.12% 178
2016
Q1
$126M Sell
1,744,696
-44,933
-3% -$3.4M 0.11% 193
2015
Q4
$151M Sell
1,789,629
-53,592
-3% -$4.45M 0.13% 173
2015
Q3
$154M Sell
1,843,221
-778,222
-30% -$65.7M 0.13% 167
2015
Q2
$219M Sell
2,621,443
-455,847
-15% -$34.7M 0.18% 129
2015
Q1
$224M Sell
3,077,290
-527,939
-15% -$37.6M 0.18% 126
2014
Q4
$249M Sell
3,605,229
-222,735
-6% -$15M 0.21% 115
2014
Q3
$248M Sell
3,827,964
-59,058
-2% -$3.74M 0.21% 114
2014
Q2
$242M Sell
3,887,022
-78,988
-2% -$4.71M 0.2% 117
2014
Q1
$233M Buy
3,966,010
+1,690,852
+74% +$94.4M 0.2% 119
2013
Q4
$116M Sell
2,275,158
-8,552
-0.4% -$428K 0.1% 232
2013
Q3
$115M Buy
2,283,710
+136,471
+6% +$7.14M 0.11% 205
2013
Q2
$105M Buy
+2,147,239
New +$117M 0.11% 199

Other funds holding LLY

AllianceBernstein's LLY Position: Q1 2026 in Review

AllianceBernstein reduced its Eli Lilly (LLY) stake by 4.2% in Q1 2026, selling an estimated $196M and leaving 4,427,764 shares worth $4.76B. The position accounts for 1.54% of the portfolio, ranked #9.

AllianceBernstein first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.97B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • AllianceBernstein held 4,427,764 shares of Eli Lilly worth $4.76B as of Q1 2026.
  • AllianceBernstein sold 193,341 Eli Lilly shares in Q1 2026, an estimated $196M.
  • Eli Lilly made up 1.54% of AllianceBernstein's portfolio in Q1 2026, its #9 holding.
  • AllianceBernstein first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's Eli Lilly position peaked at $4.97B in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.